Russia announced on Wednesday (October 14) that it had approved regulatory approval for another coronavirus COVID-19 vaccine for significant progress. The vaccine called EpiVacCorona came after Russia recently approved approval similar to the first COVID-19 vaccine called Sputnik V. In particular, Sputnik V is also the world’s first vaccine candidate with regulatory approval.
Russian President Vladimir Putin said, “We have good news. The Novosibirsk-based Vektor Center has registered a second coronavirus vaccine, EpiVacCorona,” said Russian President Vladimir Putin.
EpiVacCorona, developed by the Siberian-based Vector Institute, completed early-stage human experiments in September. The pharmaceutical company has not yet published the results of human trials, and phase 3 trials of this vaccine have not yet begun.
“We need to increase the production of the first and second vaccines,” Putin said. “We are constantly working with our foreign partners and will promote our vaccine abroad.”
The Russian government said, “The Novosibirsk-based Vektor Center has registered a second coronavirus vaccine, EpiVacCorona. Unlike Sputnik V, the first Russian vaccine, adenovirus vector-based vaccine, the new one is a promising synthetic vaccine based on peptides.” said.
Sputnik V, developed by the Gamalea Institute in Moscow, was licensed for use in Russia in August. Sputnik V, like EpiVacCorona, was registered prior to the Phase III exam. A human trial against Sputnik V is currently ongoing in Moscow.
TASS news agency reported that human trials of a new vaccine candidate, EpiVacCorona, will begin in November or December and will involve approximately 30,000 participants.
“In the near future, the first batch of 60,000 vaccinations will be produced, and the Vektor Center will start clinical trials after registration in several Russian regions with 40,000 volunteers. At the same time, we plan to start the center. Deputy Prime Minister Tatiana Golikova said.